CTOs on the Move

Arkios BioDevelopment Intl

www.arkios.com

 
Arkios BioDevelopment Intl is a Virginia Beach, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.arkios.com
  • 421 S Lynnhaven Rd Ste 101
    Virginia Beach, VA USA 23452
  • Phone: 757.631.2114

Executives

Name Title Contact Details

Similar Companies

Novascreen Biosciences Corporation

Novascreen Biosciences Corporation is a Hanover, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alvine Pharmaceuticals

Alvine Pharmaceuticals is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Poseida

Poseida Therapeutics is a clinical-stage biotechnology company translating best-in-class technology into lifesaving cell and gene therapies for patients with high unmet medical need. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as in vivo gene therapies for orphan genetic diseases. These cell therapies and the gene therapies soon to come are products of our proprietary suite of industry-leading gene engineering technologies, including the piggyBac® DNA Modification System, Cas-CLOVER™ and TAL-CLOVER™ site-specific nucleases.

Cytovance

Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in clinical and commercial manufacturing production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.

Carisma Therapeutics

Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma Therapeutics is headquartered in Philadelphia, PA.